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INTRODUCTION
The discriminative-stimulus effects of nicotine have been widely characterized in laboratory animals (e.g., Jutkiewicz, 2011; Cunningham et al., 2012 ; see Smith and Stolerman, 2009 for review), and have been related to subjective effects that promote its persistent consumption among users of tobacco or other nicotine delivery devices (e.g., Smith and Stolerman, 2009; Benowitz, 2010) . Pharmacological studies with selective agonists and antagonists additionally have identified likely mechanisms of action mediating the discriminative-stimulus effects of nicotine. For example, such effects of nicotine are readily mimicked by centrally acting nicotinic agonists with high affinity for the α 4β2 nicotinic acetylcholine receptor (nAChR) subtype but not by drugs that act selectively at other subtypes of nAChR (e.g., α 3β4 or α 7) or by drugs from other pharmacological classes (e.g., muscarinic
agents; see Smith and Stolerman, 2009 for review). Moreover, non-competitive (mecamylamine) and competitive (dihydro-β-erythroidine hydrobromide; DHβE)] antagonists that block α 4β2 nAChRs in CNS attenuate nicotine's discriminative-stimulus effects, whereas peripherally-restricted antagonists or antagonists at other nAChR subtypes (e.g., nicotinic α 7, muscarinic) are ineffective. In conjunction, such evidence strongly suggests that the discriminative-stimulus effects of nicotine are centrally-mediated, primarily via α 4β2 nAChRs (e.g., Smith and Stolerman, 2009) .
A growing body of evidence also indicates that, as with monoaminergic psychomotor stimulant drugs [e.g., cocaine, d-amphetamine, methamphetamine (MA)], the projection from ventral tegmental area (VTA) to the nucleus accumbens in the mesocorticolimbic dopamine (DA) system is a key element in brain circuitry that mediates the neurochemical and behavioral This article has not been copyedited and formatted. The final version may differ from this version.
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jpet.aspetjournals.org Downloaded from effects of nicotine. Accordingly, increases in DA neurotransmission have been proposed to mediate the reinforcing effects of nicotine and its consumption (e.g., Di Chiara, 2000; Smith and Stolerman, 2009 ). The involvement of common neural substrates also has led to the suggestion that nicotine and monoaminergic psychomotor stimulant drugs might engender overlapping subjective effects and, in laboratory animals, discriminative-stimulus effects (e.g., Smith and Stolerman, 2009) . Data from some, but not all, previous studies in nicotine-and stimulant (cocaine-or d-amphetamine)-trained subjects have supported this suggestion (see Smith and Stolerman, 2009 for review), and have profitably advanced our understanding of the stimulantlike effects of nicotine and other nicotinic ligands. For example, using the psychomotor stimulant MA as a discriminative-stimulus in rats, our recent studies in rats suggest that: a) nicotinic agonists may vary in the extent to which they produce MA-like stimulant effects; b) α 4β2 nAChR-mediated actions may play an important role in the MA-like stimulant effects of nicotinic agonists; and c) varenicline dose-dependently antagonized the MA-like stimulant actions of nicotine, consistent with the view that nicotinic partial agonists may help manage nicotine addiction and tobacco consumption (Rollema et al., 2007; Desai and Bergman, 2010 ).
The present research was conducted to further investigate the discriminative-stimulus effects of nicotine and related compounds. The goals of this work were to determine whether the discriminative-stimulus effects of MA and nicotine overlap in primate species and, if so, to examine the pharmacology of that overlap with a range of nAChR ligands. Using standard drug discrimination procedures, squirrel monkeys first were trained to distinguish a moderate dose of 0.1 mg/kg MA from saline. Next, the effects of monoamine uptake inhibitors (MA, cocaine), DA D 1 -and D 2 -like agonists [SKF82958, R-(-)-NPA], and a selective serotonin reuptake
inhibitor (citalopram) were tested to confirm the role of dopaminergic mechanisms in these This article has not been copyedited and formatted. The final version may differ from this version.
jpet.aspetjournals.org Downloaded from effects of MA (Tidey and Bergman, 1998 and Arenric, 1994; Baido and Daly, 1994; Hahn et al., 2003; Rollema et al., 2007] . Substitution tests also were conducted with the α 7 nAChR subtype-selective agonists, anabasine and anabaseine (de Fiebre et al., 1995; Kem et al., 1997) . Finally, drug interaction studies were conducted to compare modulation of the MA-like discriminative-stimulus effects of nicotine by the α 4β2 competitive antagonist DHβE (Williams and Robinson, 1984) 
Apparatus
The apparatus and methodology were comparable to those employed previously (Kangas et al. 2013; Tidey and Bergman, 1998) . During experimental sessions, monkeys sat in customized Plexiglas chairs (Kelleher and Morse, 1968) 
MA Discrimination
Subjects first were trained to press each of the two response levers under a 10-response fixed-ratio (FR10) schedule of stimulus-termination. Under this schedule, a brief, mild electric stimulus (200 ms; 3 mA) was programmed for delivery to the tail every 10 s during the illumination of red lights on the front panel. The completion of ten consecutive lever-press responses (FR10) on one lever within 10 s turned off the red lights and the associated program of current delivery. The completion of each FR10 also initiated a 50-sec timeout (TO) period, during which all lights in the chamber were extinguished and responding had no programmed consequences. The delivery of four electric stimuli prior to completion of the FR requirement also turned off all lights, terminated the program of stimulus delivery, and initiated the 50-sec TO period. Once performance was stable on both levers under the FR10 response requirement, subjects were trained to discriminate i.m. injections of 0.1 mg/kg MA from i.m. injections of saline (Tidey and Bergman, 1998 (Spealman, 1995) . Thus, in the present study, we lowered the training dose of MA from the highly restrictive dose of 0.32 mg/kg to 0.1 mg/kg to assess the possibility of overlapping discriminative-stimulus effects among compounds from different pharmacological classes. After MA injection, only responses on one lever were reinforced; after saline injection, only responses on the other lever were reinforced.
The assignment of MA-associated and saline-associated levers was counterbalanced across monkeys. During all training sessions, responses on the inappropriate lever reset the FR response requirement on the injection-appropriate lever.
When discrimination performance was stable from day to day at or above criterion (90% After all drugs were studied for their ability to substitute for MA, drug interaction studies were conducted to determine how pretreatment with selected compounds [varenicline, (-)-cytisine, and DHβE] modified the MA-like effects of nicotine. Pretreatment times were based on data from preliminary experiments and published reports Rollema et al., 2007; Desai and Bergman, 2010) Data were further analyzed to compare potency and maximum effects among drugs, to evaluate drug interactions, and to examine correspondence between the effects of nicotinic drugs in the present experiments and their published affinities for different subtypes of the nicotinic receptor. As appropriate, ANOVA followed by Dunnett's t-test or a paired t-test was used to evaluate statistical significance of averaged data (defined at the 95% level of confidence; p < 0.05). When appropriate, interpolation or linear regression using Bioassay Software (Bioassay version Beta 6.2; MED Associates Inc.) was used to calculate ED 50 values (S.E.M. for interpolation and 95% confidence limits for regression) from data points on the linear portions of the dose-response functions (Snedecor and Cochran, 1967 receptor subtype, and affinities relative to nicotine were averaged across studies (see Table 1 ).
This article has not been copyedited and formatted. The final version may differ from this version. were not studied to avoid untoward effects, e.g. convulsions, previously observed with high doses of serotonin-selective reuptake inhibitors (Spealman, 1995) . Although cocaine, like MA, increased responding in a dose-related manner, response rates were not significantly changed from vehicle values by any of the drugs studied (Fs 4,15 ≤ 1.23; Ps > 0.05; Fig. 1 ; bottom panels).
Nicotinic agonists. Nicotine produced dose-dependent increases in responding on the MA- Fig. 2 ; bottom panels). However, the highest doses of each drug produced observable effects, including profuse salivation and emesis (see below and Table 2 ).
The nicotinic agonists isoarecolone, anabaseine, anabasine, and varenicline also produced dose-dependent increases in responding on the MA-associated lever ( dose (0.18 mg/kg) and rates of responding were comparable to control values. The two highest doses of isoarecolone also produced comparable levels of responding on the MA-associated lever; however, the 0.5 log unit increase in dose from 3.2 to 10 mg/kg produced a small, albeit non-significant, increase in responding on the MA-associated lever and a decrease in response rate to 60% of control values, precluding a more definitive characterization of its efficacy. No indication of a plateau in MA-like effects was apparent with either anabasine or anabaseine.
Anabasine did not alter mean rates of responding over the range of doses studied, whereas anabaseine reduced response rate in a dose-dependent manner and, following the highest cumulative dose (3.2 mg/kg) nearly or completely eliminated responding. As with nicotine and regardless of the presence or absence of effects on response rates, the highest cumulative doses of each of these nicotinic agonists produced untoward physiological signs that precluded further testing (see below and Table 2 ).
The rank order of potency with which nicotinic agonists produced MA-like effects was: (Table 1) . Based on ED 50 estimates, isoarecolone and the two enantiomers of epibatidine were, respectively, the least and most potent nicotinic ligands in the present studies, and approximately 85-to 80-fold less and more potent than nicotine, respectively. The remaining drugs were approximately 3-fold (varenicline) and 10 to 20-fold (anabaseine, anabasine) less potent than nicotine in producing MA-like discriminative-stimulus effects (Table   1 ).
In contrast to the above ligands, (-)-cytisine and (-)-lobeline failed to substitute for the training dose of MA, producing ≤ 30% responding on the MA-associated lever over the range of doses that could be studied ( significantly altered following the highest cumulative doses of (-)-cytisine and (-)-lobeline, untoward observable effects precluded the administration of higher doses (see below; Table 2 ).
Observable effects of nicotinic agonists. The observable effects of nicotinic agonists in the present study included untoward physiological signs following one or more cumulative doses of each drug ( Table 2 ). Regardless of the presence or absence of MA-like discriminative-stimulus effects, the highest cumulative doses of each agonist produced profuse salivation in all subjects that often was followed by emesis. In addition to producing excessive salivation and emesis, the highest cumulative doses of isoarecolone, anabasine, (-)-cytisine, and (-)-lobeline produced tremor in individual subjects (Table 2 ). Convulsions after cumulatively administered doses of 3.2 or 10 mg/kg lobeline also were noted in two subjects; these signs were quickly and completely attenuated by i.m. diazepam (1.0 mg/kg). Based on ED 50 values, the effects of nicotine were displaced approximately 7-and 14-fold rightward by pretreatment with 0.032 mg/kg and 0.1 mg/kg (-)-cytisine, respectively (Table 3) .
Antagonism of nicotine
Like varenicline, pretreatment doses of (-)-cytisine did not substantively alter nicotine's effects on response rates, and only moderate (<50%) decreases from vehicle-control rates of responding were observed following their combination (Fig. 5 , bottom right panel).
Although not studied separately, neither the α 4β2 antagonist DHβE nor the α 4β2 partial agonists varenicline and (-)-cytisine appeared to attenuate the emetic effects of cumulative doses of nicotine that produced full substitution for MA. As described above, tremor or frank convulsions following treatment with several nicotinic ligands was evident in the present studies, This article has not been copyedited and formatted. The final version may differ from this version. Nicotine and the enantiomers of epibatidine also produced dose-dependent increases in MA-associated responding, and fully (or, in the case of (+)-epibatidine, nearly fully) substituted for MA without greatly altering response rates. The comparable effects of these nicotinic full agonists are consistent with their similar nicotinic α 4β2 subtype selectivity (see Table 1 ) and with previous drug discrimination data from nicotine-trained rodents (Reavill et al., 1987; Damaj et al., 1994) . They contrast somewhat with data from MA-trained rats in which only nicotine fully substituted for the training dose of MA (Desai and Bergman, 2010) . In those studies, 0.001 mg/kg of both (+)-epibatidine and (-)-epibatidine produced approximately 60-70% responding on the MA-associated lever, whereas a 3-fold increase in the dose of both enantiomers completely eliminated responding, precluding further testing. Differences in the two studies may reflect species-related differences in vulnerability to the rate-decreasing effects of the epibatidine enantiomers or, alternatively, differences in the resistance of responding maintained by stimulusThis article has not been copyedited and formatted. The final version may differ from this version. Like varenicline, isoarecolone is characterized as an α 4β2-selective ligand and can fully reproduce the discriminative-stimulus effects of nicotine in nicotine-trained rats (Reavill et al., 1987; Damaj et al., 1994) . Based upon other behavioral and biochemical findings, however, isoarecolone has been forwarded as a nicotinic partial agonist (Reavill et al., 1987; Mirza et al. 1996; Whiteaker et al., 1995 , Hahn et al. 2003 Shoaib, 2006 The minor tobacco alkaloids anabasine and anabaseine produced dose-related increases in responding on the MA-associated lever without nicotine-like full substitution or a vareniclinelike plateau in MA-like effects. Both drugs previously have displayed α 7 and, with lower efficacy, α 4β2 receptor-mediated agonist actions (Arendash et al., 1995; Kem et al., 1997; Stevens et al., 1998) . Possibly, the limited nicotine-like effects of anabasine and anabaseine in the present experiments reflect relatively low efficacy at the α 4β2 receptor (e.g., Takada et al., 1989; Brioni et al., 1994; de Fiebre et al., 1995; Stolerman et al., 1995; Desai and Bergman, 2010) . Alternatively, (-)-Cytisine and (-)-lobeline, which have high nAChR affinity and α 4β2 subtypeselectivity (see Table 1 ), failed to engender MA-like discriminative-stimulus effects in the present studies. Previously, (-)-cytisine was shown to both partially substitute for nicotine in rats and block its discriminative-stimulus effects, consistent with its characterization as a nicotinic partial agonist (Stolerman et al., 1984; Reavill et al., 1990; Brioni et al., 1994; Jutkiewicz et al., 2011; Cunningham et al., 2012) . The absence of MA-like effects in the present studies suggest Dwoskin and Crooks, 2002) . Thus, (-)-lobeline has been shown to substitute for a low training dose of cocaine, yet attenuate the effects of a higher training dose of cocaine or methamphetamine (Miller et al., 2001; Harrod et al., 2003; Desai et al., 2003; Cunningham et al., 2006) . Further indicative of its poorly-understood actions, (-)-lobeline has been reported to produce nicotine-like effects in studies of locomotor activity, but not in place conditioning, self-administration, or drug discrimination studies (Fudala and Iwamoto, 1986; Corrigall and Coen, 1989; Reavill et al., 1990; Stolerman et al., 1995; Harrod et al., 2003) . Although the absence of MA-like effects in the present study is not inconsistent with its characterization as a nicotinic partial agonist, additional data showing that (-)-lobeline, like varenicline, can antagonize such effects of nicotine would strengthen this categorization.
Although only isoarecolone and anabaseine decreased response rates, the highest cumulative doses of all nicotinic agonists produced untoward physiological signs (emesis, tremor, or convulsions) that precluded the study of higher doses (see Table 2 ). However, profuse salivation and emesis alone did not appear to interfere with discrimination behavior, e.g., nicotine and epibatidine fully substituted for MA despite profuse salivation and emesis in all subjects. Although the precise mechanism responsible for these adverse physiological signs remains unclear, it is notable that they can be produced by both α 4β2 nAChR agonists and antagonists as well as by α 7-selective ligands (Damaj et al. 1999; Dobelis et al. 2003) . Thus, it is unlikely that these signs reflect actions at a single subtype of nicotinic receptor.
Pretreatment with the competitive antagonist DHβE and the α 4β2-selective partial agonists varenicline and (-)-cytisine shifted the dose-effect function for nicotine's MA-like effects rightward, complementing similar results in nicotine-trained rats (Stolerman et al., 1997; Jutkiewicz et al., 2011) . Although each drug served as a surmountable antagonist, the range of Table 1 ). These observations parallel a similar analysis in MA-trained rats, and are consistent with the ability of the α4β2 receptor blocker DHβE, but not the α7 receptor blocker MLA, to antagonize nicotine's discriminative-stimulus effects (Brioni et al., 1996; Desai and Bergman, 2010) . In concert with the antagonist effects of DHβE and the partial agonists predominantly mediated by their actions at the α4β2 nAChR (Reavill et al., 1987; 1988; Stolerman et al., 1995; Desai and Bergman, 2010) .
This article has not been copyedited and formatted. The final version may differ from this version. potency of nicotinic drugs relative to nicotine, based on ED 50 values, for engendering MAassociated lever responding (from Table 1 ). Isoarecolone was excluded from this correlation analysis at the α7 nicotinic receptor subtypes because affinity values obtained at this site are not clearly defined (see Table 1 ).
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